Press Releases

Date Title and Summary Additional Formats
Toggle Summary Anthera Pharmaceuticals to Participate in the BIO CEO & Investor Conference and SunTrust Robinson Humphrey’s 4th Annual Orphan Drug Day
HAYWARD, Calif. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals , Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and B-cell associated renal
View HTML
Toggle Summary Anthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of Sollpura
HAYWARD, Calif. , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals , Inc. (Nasdaq:ANTH) is pleased to announce that the final patient has completed the last visit in the primary treatment phase of RESULT, a Phase 3 clinical study of Sollpura for exocrine pancreatic insufficiency (“EPI”)
View HTML
Toggle Summary Anthera Receives Positive Nasdaq Listing Determination
HAYWARD, Calif. , Jan. 25, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that on January 24, 2018 , Anthera received formal notice that the Nasdaq Hearings Panel granted Anthera’s request for inclusion on The Nasdaq Capital Market .
View HTML
Toggle Summary Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura: Study On Schedule for Topline Data this Quarter
HAYWARD, Calif. , Jan. 22, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced a positive outcome of the second, pre-specified interim futility analysis for the RESULT Phase 3 clinical study of Sollpura for the treatment of Exocrine Pancreatic Insufficiency (“EPI”).
View HTML
Toggle Summary Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering
HAYWARD, Calif. , Jan. 09, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals , Inc. (Nasdaq:ANTH) today announced that it has completed the second closing of the private placement of its equity securities (“PIPE”) with certain institutional and accredited investors.  The PIPE transaction was
View HTML
Toggle Summary Anthera Pharmaceuticals Announces Results of Special Meeting of Stockholders
HAYWARD, Calif. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals , Inc. (Nasdaq:ANTH) is pleased to announce the results of the Special Meeting of Stockholders held on January 5 , 2018.  Shareholders approved all of the proposed business matters which included: (i) approval of the second
View HTML
Toggle Summary Anthera Pharmaceuticals Announces Appointment of Patrick Murphy as Senior Vice President, Manufacturing
HAYWARD, Calif. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals , Inc. (Nasdaq:ANTH) today announced the appointment of Patrick Murphy as Senior Vice President, Manufacturing.  Patrick brings over 35 years of experience in global manufacturing, product development, and
View HTML
Toggle Summary Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura
HAYWARD, Calif. , Dec. 11, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals , Inc. (Nasdaq:ANTH) today announced a positive outcome of the pre-specified interim futility analysis for the RESULT Phase 3 clinical study of Sollpura for the treatment of Exocrine Pancreatic Insufficiency (“EPI”).  The
View HTML
Toggle Summary Anthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans Appeal
Delisting notice was expected as part of the compliance extension previously granted by Nasdaq Continue “ANTH” listing until formal hearing process is complete with the Nasdaq Hearings Panel  HAYWARD, Calif. , Nov. 17, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals , Inc. (Nasdaq:ANTH) announced
View HTML
Toggle Summary Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura
HAYWARD, Calif. , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals , Inc. (Nasdaq:ANTH) today announced that patient recruitment is now complete for the Phase 3 RESULT clinical study of Sollpura for the treatment of Exocrine Pancreatic Insufficiency (“EPI”) caused by cystic fibrosis.
View HTML